1
Clinical Trials associated with Autologous Dendritic Cell HIV Vaccination(National Institute of Allergy & Infectious Diseases)Randomized Phase I Evaluation of Immunization With Highly Conserved HIV-1 Derived Peptides and Influenza Matrix Peptide in HIV-1-Infected Subjects on Highly Active Antiretroviral Therapy (HAART) Using Autologous Dendritic Cells Derived From Adherent Monocytic Precursors
This study will evaluate the safety of and immune responses to a dendritic cell vaccination for HIV-1 infection. The vaccine will be made from a patient's own cells combined with small fragments of HIV-1 (made synthetically in a laboratory). These cells will be administered back to the patient either into a vein (intravenously) or the skin (subcutaneously).
100 Clinical Results associated with Autologous Dendritic Cell HIV Vaccination(National Institute of Allergy & Infectious Diseases)
100 Translational Medicine associated with Autologous Dendritic Cell HIV Vaccination(National Institute of Allergy & Infectious Diseases)
100 Patents (Medical) associated with Autologous Dendritic Cell HIV Vaccination(National Institute of Allergy & Infectious Diseases)
100 Deals associated with Autologous Dendritic Cell HIV Vaccination(National Institute of Allergy & Infectious Diseases)